Elite Pharmaceuticals, Inc. Announces 2013 Fiscal Year End Conference Call on Monday, June 24, 2013

Elite Pharmaceuticals, Inc. Announces 2013 Fiscal Year End Conference Call on
Monday, June 24, 2013

NORTHVALE, N.J., June 19, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc.
(OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and
commercializing oral sustained and controlled release product formulations and
generics with high barriers to entry, announced today the Company will host a
conference call on Monday, June 24, 2013 at 11:00 AM EDT to review the year
end results of operations and provide an update on recent business
developments. Company executives will also conduct a question and answer
session following their remarks.

To access the conference call:

  Domestic callers: (800) 346-7359
  International callers: (973) 528-0008
  Conference Entry Code: 98840

A digital telephone replay will be available approximately one hour after the
conclusion of the call for two weeks until July 8, 2013 by dialing:

  Domestic callers: (800) 332-6854
  International callers: (973) 528-0005
  Conference entry code: 98840

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release
products. Elite's strategy includes assisting partner companies in the life
cycle management of products to improve off-patent drug products and
developing generic versions of controlled release drug products with high
barriers to entry. Elite has five commercial products currently being sold, an
additional product approved and soon to be launched, and one additional
product under review pending approval by the FDA.Elite's lead pipeline
products include abuse resistant opioids utilizing the Company's patented
proprietary technology, and a once-daily opioid.They are sustained release
oral formulations of opioids for the treatment of chronic pain, which address
two of the limitations of existing oral opioids: the provision of consistent
relief of baseline pain levels and deterrence of potential abuse.Elite also
provides contract manufacturing for Actavis and Ascend Laboratories
(previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem
Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new
product, with Hi-Tech Pharmacal to develop an intermediate for a generic
product, and a Hong Kong based company to develop a branded product for the
United States market and its territories.Elite operates a GMP and DEA
registered facility for research, development, and manufacturing located in
Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Including those related
to the effects, if any, on future results, performance or other expectations
that may have some correlation to the subject matter of this press release,
readers are cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, delays, uncertainties, inability
to obtain necessary ingredients and other factors not under the control of
Elite, which may cause actual results, performance or achievements of Elite to
be materially different from the results, performance or other expectations
that may be implied by these forward-looking statements. These risks and other
factors, including, without limitation, the Company's ability to obtain
sufficient funding under the LPC Agreement or from other sources, the timing
or results of pending and future clinical trials, regulatory reviews and
approvals by the Food and Drug Administration and other regulatory
authorities, intellectual property protections and defenses, and the Company's
ability to operate as a going concern, are discussed in Elite's filings with
the Securities and Exchange Commission, including its reports on forms 10-K,
10-Q and 8-K. Elite undertakes no obligation to update any forward-looking
statements.

CONTACT: For Elite Pharmaceuticals, Inc.
         Dianne Will, Investor Relations, 518-398-6222
         Dianne@elitepharma.com
         www.elitepharma.com

Elite Pharmaceuticals, Inc Logo